BrisDoc Patient care by people who care

NHS

Charlotte Keel MEDICAL PRACTICE

# Administration of Inclisiran Injections Standard Operating Procedure SOP

| Version: | Owner: | Created: |
|---|---|---|
| 2.1 | Jodie Godfrey | 1st February 2022 |
| **Published:** | **Approving Director:** | **Next Review** |
| 02/01/2025 | Rhys Hancock (Director of Nursing, Allied Health Professionals and Governance.) | 02/01/2026 |

# Contents

# Administration of Inclisiran Injections

## Introduction

Inclisiran is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults with a history of cardiovascular disease whose LDL cholesterol concentrations are persistently 2.6mmol/l or more despite maximum tolerated lipid-lowering therapy.

## Indication

Primary hypercholesterolaemia or mixed dyslipidaemia (in combination with a statin, or with a statin and other lipid-lowering therapies, or with other lipid-lowering therapies or alone if a statin contra-indicated or not tolerated).

https://bnf.nice.org.uk/drug/inclisiran.html [Accessed 18/02/2022].

No dose adjustment in patients over 65, mild or moderate hepatic impairment (use with caution in severe), or renal impairment (any stage, but use with caution in severe).

## Administration

Inclisiran may be administered by a trained nurse following recent prescription which should be visible on EMIS medications record, or a Patient Specific Direction (PSD).

Leqvio® 284 mg solution for injection in pre-filled syringe.

Inject subcutaneously into the abdomen; alternatively inject subcutaneously into the thigh or upper arm.

Initial doses 0 and 3 months, maintenance dose every 6 months.

## Missed doses

If a planned dose is missed by less than 3 months, Inclisiran should be administered and dosing continued according to the patient's original schedule.

If a planned dose is missed by more than 3 months, a new dosing schedule should be started – Inclisiran should be administered initially, again at 3 months, followed by every 6 months.

https://www.medicines.org.uk/emc/product/12039/smpc#gref [Accessed 18/02/2022].

## Storage

This medicinal product does not require any special storage conditions. Do not freeze.

A stock will be kept in room 7.

## Monitoring

50% reduction in LDL cholesterol concentrations should be seen 30-60 days after treatment.

Repeat full lipid profile 30-60 days following 2nd initial dose (given at 3 months).

If possible, blood test should be booked by nurse administering second initial dose, otherwise patient should be instructed to book via reception.

## Documentation

Problem - CVD/Dyslipidaemia/Hypercholesterolaemia.

Procedure – use code 'subcutaneous injection', and free text in manufacturer, expiry date, batch number, route.

Follow-up – use lipid lowering therapy code and put date when next injection due. Also add Ardens diary recall for repeat lipids 1/12 after 2nd dose (at 3 months).

## Prescription

Nurse administering injection to add prescription to EMIS (medication, add drug, issue, approve and complete).

## Recalls

Recall code in diary - lipid lowering therapy.

LDT/CST will run monthly lipid lowering therapy report.

## References

**BNF** https://bnf.nice.org.uk/drug/inclisiran.html [Accessed 18/02/2022]

**EMC** https://www.medicines.org.uk/emc/product/12039/smpc#PRODUCTINFO [Accessed 18/02/2022]

**NICE** https://www.nice.org.uk/guidance/ta733/resources/inclisiran-for-treating-primary-hypercholesterolaemia-or-mixed-dyslipidaemia-pdf-82611252825541 [Accessed 18/02/2022]

## Changes Register

| Date | Version | Author | Changes |
|---|---|---|---|
| 01/02/2022 | 1 | LT | New SOP |
| 05/05/2023 | 2 | LT | Full Review |
| 13/11/2024 | 2.1 | JG | Full review |